Nucleic acid cancer immunotherapy
US7960361B2 · kind B2 · utility
3Cited by
6References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 25, 2008 |
| Grant date | Jun 14, 2011 |
| Priority date | — |
| Expiry date | Nov 13, 2028 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/545
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for stimulating a immune response against IL-13Rα2 in a subject having or at risk for developing a disease having cells expressing IL-13Rα2 includes the steps of formulating the anti-cancer vaccine outside of the subject and administering the vaccine to the subject in an amount sufficient to stimulate an immune response against IL-13Rα2 in the subject. A composition for stimulating a immune response against IL-13Rα2 in a subject having or at risk for developing a disease having cells expressing IL-13Rα2 includes an isolated agent that can stimulate immune response against IL-13α2.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.